Navigation Links
Khosla Ventures and BIOeCON Form KiOR Inc.

Technology Development for the Conversion of Biomass to Bio-oil

MENLO PARK, California and HOEVELAKEN, The Netherlands, November 1 /PRNewswire/ -- Khosla Ventures and BIOeCON announce today the formation of their joint venture KiOR Inc. Khosla Ventures, will provide the Series A funding, whereas BIOeCON will bring its knowledge and intellectual property for the 'Biomass Catalytic Cracking Process' (BCC). KiOR Inc. will focus on the further development and commercialization of the BCC technology as well as prepare for raising significantly more capital in the next two to three years.

BCC technology converts lignocellulosic biomass, found in grass, wood, and various agricultural and forestry wastes, into a bio-oil product that can be further upgraded to transportation fuels. The conversion of cellulosic biomass to bio-oil represents a significant commercial opportunity that also offers important benefits, including using post-harvesting waste rather than competing with food crops; promoting environmental sustainability; reducing reliance on fossil fuels such as crude oil; and enabling economic development and job creation in rural areas.

"The key technical problem in the conversion of cellulosic biomass into usable fuels is how to open up the inaccessible solid fibrous 'woody' material, so that it can be effectively transformed. Most of the existing processes to unlock the woody structures are quite costly and intensive of energy or chemicals," says Paul O'Connor, founder and president of BIOeCON. "BIOeCON has developed a simple non-energy intensive way to make the woody biomass accessible to catalysts and convert to a bio-oil product with significantly improved product properties compared to other thermal-chemical processes.

Doug Cameron, Khosla Ventures' Chief Scientific Advisor: "BIOeCON has a strong R&D network and solid scientific fundamentals. We have done a thorough evaluation of the technology and research programs and believe this can be a breakthrough technology."

"Securing funding from a strategic and visionary venture capital company like Khosla Ventures is a major step forward", says Rob van der Meij, CEO of KiOR Inc." Khosla's experience and expertise in technology startups is unmatched in the industry and we are looking forward to the acceleration that Khosla Ventures no doubt will bring."

KiOR's concept and approach is unique and has the potential to become a large scale, widely applied technology, that can improve energy availability and sustainability to both the developed and developing world. The BCC technology unlocks the energy of vast amounts of biomass waste and converts it into a high valued energy product. This will not only reduce net carbon dioxide emission, but can also improve the energy independence of many countries.


BIOeCON was founded in 2006 by Paul O'Connor with the aim to develop new, large scale technology to convert biomass, particularly the recalcitrant polymeric biomass residue, in a more efficient and cost-effective way to valuable molecules which can be utilized by the chemical and energy industry. BIOeCON is a privately funded company, which operates through an international network of top-scientists and institutions to bring together know-how, expertise and experience from heterogeneous catalysis, biomass processing, process development and technology commercialization. BIOeCON is based in Hoevelaken, the Netherlands.

About Khosla Ventures

Khosla Ventures offers venture assistance, strategic advice and capital to entrepreneurs. The firm helps entrepreneurs extend the potential of the Internet to new markets such as mobile and supports breakthrough scientific work such as bio refineries. Vinod Khosla founded the firm in 2004 and was joined in 2006 by two partners. The partners have been involved in founding or growing billion dollar businesses such as Sun Microsystems, Juniper Networks and AOL. Vinod has been labeled the #1 VC multiple times by Forbes and Fortune recently labeled him as one of the nation's most influential ethanol advocates, noting "there are venture capitalists, and then there's Vinod Khosla." The firm's capital comes entirely from its own partners and a portion of all profits are donated to charitable causes, with an emphasis on micro-finance, education, the environment and affordable housing. Khosla Ventures is based in Menlo Park, California, USA.

Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Tech companies get commerce loans for new ventures
2. Conference will focus on financing of early-stage ventures
3. Badger Ventures plans to fund IT; partisan stem-cell battle; BadgerNet draws fire
4. New Madison VC firm Badger Ventures looks for next big IT entrepreneurs
Post Your Comments:
(Date:11/27/2015)... 2015 /PRNewswire/--  Mallinckrodt plc (NYSE: MNK ), ... has closed the sale of its global contrast media ... Euronext) in a transaction valued at approximately $270 million. ... a total of approximately 1,000 employees spread across the ... Louis area. This entire workforce and the ...
(Date:11/27/2015)... PUNE, India , November 27, 2015 ... --> Growing popularity of companion ... emerging in cancer biomarkers market with pharmaceutical ... develop in-demand companion diagnostic tests. ... --> Complete report on global ...
(Date:11/26/2015)... November 26, 2015 --> ... specializing in imaging technologies, announced today that it has received ... of the Horizon 2020 European Union Framework Programme for Research ... clinical trial in breast cancer. , --> ... --> --> The study aims ...
(Date:11/25/2015)... 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) announced ... stockholder rights plan (Rights Plan) in an effort to ... (NOLs) under Section 382 of the Internal Revenue Code ... PharmAthene,s use of its NOLs could be substantially limited ... in Section 382 of the Code. In general, an ...
Breaking Biology Technology:
(Date:11/2/2015)... Calif. , Nov. 2, 2015  SRI International ... million to provide preclinical development services to the National ... contract, SRI will provide scientific expertise, modern testing and ... variety of preclinical pharmacology and toxicology studies to evaluate ... --> The PREVENT Cancer Drug Development Program ...
(Date:10/29/2015)... Calif. , Oct. 29, 2015  The J. ... new report titled, "DNA Synthesis and Biosecurity: Lessons Learned ... the Department of Health and Human Services guidance for ... in 2010. --> ... it also has the potential to pose unique biosecurity ...
(Date:10/29/2015)... ARBOR, Mich. , Oct. 29, 2015 /PRNewswire/ ... Eurofins Genomics for U.S. distribution of its DNA ... DNA-seq kit and Rubicon,s new ThruPLEX Plasma-seq kit. ... to enable the preparation of NGS libraries for ... plasma for diagnostic and prognostic applications in cancer ...
Breaking Biology News(10 mins):